| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | 不含卤素的聚合物和利用它的汽车电线 | CN200480035822.8 | 2004-02-27 | CN100509939C | 2009-07-08 | 金吾荣; 尹承勋; 林和俊 |
| 本发明公开一种用于不含卤素的汽车电缆的绝缘组合物，该绝缘组合物包含基质树脂，以及按100重量份的该基质树脂计为50～200重量份的金属氢氧化物阻燃剂和0.5～20重量份的抗氧剂，其中所述基质树脂由1～80重量份的聚乙烯树脂，1～80重量份的乙烯共聚物树脂，及1～20份的聚乙烯、丙烯酸酯和马来酸酐的三元共聚物构成。本发明的组合物和包含它的汽车电缆减少有毒气体和烟的产生，是对生态环境友好的。另外，它们的物理性能如阻燃性、耐磨性、耐刮性、硬度和耐热性优异，并且能够高速挤出。 | ||||||
| 2 | 不含卤素的聚合物和利用它的汽车电线 | CN200480035822.8 | 2004-02-27 | CN1890316A | 2007-01-03 | 金吾荣; 尹承勋; 林和俊 |
| 本发明公开一种用于不含卤素的汽车电缆的绝缘组合物，该绝缘组合物包含基质树脂，以及按100重量份的该基质树脂计为50～200重量份的金属氢氧化物阻燃剂和0.5～20重量份的抗氧剂，其中所述基质树脂由1～80重量份的聚乙烯树脂，1～80重量份的乙烯共聚物树脂，及1～20份的聚乙烯、丙烯酸酯和马来酸酐的三元共聚物构成。本发明的组合物和包含它的汽车电缆减少有毒气体和烟的产生，是对生态环境友好的。另外，它们的物理性能如阻燃性、耐磨性、耐刮性、硬度和耐热性优异，并且能够高速挤出。 | ||||||
| 3 | 人抗人白介素－18抗体及其片断和它们的利用方法 | CN200480011618.2 | 2004-04-30 | CN100457901C | 2009-02-04 | 杉村和久; 中西宪司; 中岛敏博 |
| 本发明的源自人的人抗人IL-18抗体是对于人的IL-18的抗体，其含有由以下(a)或(b)的多肽组成的H链的互补性决定区，和由(c)或(d)的多肽组成的、对人白介素-18的L链的互补性决定区。(a)由序列号4～6所示的氨基酸序列组成的多肽。(b)在(a)中所述的多肽的异构体、成为H链的互补性决定区的多肽。(c)由序列号10～12所示的氨基酸序列组成的多肽。(d)在(c)中所述的多肽的异构体、成为L链的互补性决定区的多肽。由此，提供人抗人IL-18抗体以及其利用方法成为可能。 | ||||||
| 4 | (R/S)利福霉素衍生物，它们的制备和药物组合物 | CN200580030859.6 | 2005-07-21 | CN101031572B | 2010-12-08 | C·Z·丁; 马振坤; 李静; S·哈兰; 何勇; K·P·迈纳; I·H·金; J·C·朗古德; 靳亚非; K·D·康姆布林克 |
| 具有以下通式(I)结构的利福霉素衍生物(氢醌和相应的醌(C1-C4)形式)：或其盐、水合物或前药；其中优选的R1包含氢或乙酰基，优选的R2包含氢、甲基或其他低级烷基；其中星号(*)表示具有手性中心的碳，其中绝对构型是指定为R或S。还描述了制备前述的利福霉素衍生物的方法。该化合物表现出抗微生物活性，包括作用于耐药性微生物。流程图A：式I化合物的制备。 | ||||||
| 5 | (R/S)利福霉素衍生物，它们的制备和药物组合物 | CN200580030859.6 | 2005-07-21 | CN101031572A | 2007-09-05 | C·Z·丁; 马振坤; 李静; S·哈兰; 何勇; K·P·迈纳; I·H·金; J·C·朗古德; 靳亚非; K·D·康姆布林克 |
| 具有以下通式(I)结构的利福霉素衍生物(氢醌和相应的醌(C1－C4)形式)：或其盐、水合物或前药；其中优选的R1包含氢或乙酰基，优选的R2包含氢、甲基或其他低级烷基；其中星号(*)表示具有手性中心的碳，其中绝对构型是指定为R或S。还描述了制备前述的利福霉素衍生物的方法。该化合物表现出抗微生物活性，包括作用于耐药性微生物。 | ||||||
| 6 | 人抗人白介素－18抗体及其片断和它们的利用方法 | CN200480011618.2 | 2004-04-30 | CN1780911A | 2006-05-31 | 杉村和久; 中西宪司; 中岛敏博 |
| 本发明的源自人的人抗人IL－18抗体是对于人的IL－18的抗体，其含有由以下(a)或(b)的多肽组成的H链的互补性决定区，和由(c)或(d)的多肽组成的、对人白介素－18的L链的互补性决定区。(a)由序列号4～6所示的氨基酸序列组成的多肽。(b)在(a)中所述的多肽的异构体、成为H链的互补性决定区的多肽。(c)由序列号10～12所示的氨基酸序列组成的多肽。(d)在(c)中所述的多肽的异构体、成为L链的互补性决定区的多肽。由此，提供人抗人IL－18抗体以及其利用方法成为可能。 | ||||||
| 7 | 3′-羟基苯并嗪并利福霉素衍生物的制备方法和含有它们的抗菌剂 | CN89107160.1 | 1989-09-16 | CN1042357A | 1990-05-23 | 山根毅彦; 橋爪卓士; 山下胜治; 细江和典; 久世文幸; 渡边清 |
| 制备式(I)利福霉素衍生物或其药用盐，式中A为式的基团，其中R1为有4或5个碳原子的烷基，或为有3-5个碳原子的链烯基，或者为式的基团，其中n为3或4。该利福霉素衍生物(I)对于革兰氏阳性细菌和耐酸细菌具有显著的抗菌活性，并且对于结核杆菌也具有显著的抗菌活性。 | ||||||
| 8 | 包含3-甲酰基利福霉素SV和3-甲酰基利福霉素S的3-(4-肉桂基-1-哌嗪基)氨基衍生物的药物制剂以及它们的制备方法 | CN201380053241.6 | 2013-08-09 | CN104736152B | 2018-01-23 | R·G·康斯坦丁诺瓦; 基里尔·阿瑟诺夫·尼诺夫; 卫理士卡·里列瓦·阿波斯托洛娃-迪莫瓦; 伊夫提米亚·伊万诺瓦·斯戴凡诺瓦; 罗森·克鲁莫夫·科伊特切夫 |
| 本发明涉及制备包含作为活性物质的3‑甲酰基利福霉素SV和3‑甲酰基利福霉素S的3‑(4‑肉桂基‑1‑哌嗪基)‑氨基衍生物的药学上可接受的制剂的方法，所述药学上可接受的制剂具有针对革兰氏阳性和革兰氏阴性微生物以及针对结核分枝杆菌(tuberculous micobacteria)(包括非典型的和利福霉素抗性的)的高活性，并且涉及用于制备3‑甲酰基利福霉素SV和3‑甲酰基利福霉素S的3‑(4‑肉桂基‑1‑哌嗪基)‑氨基衍生物的方法。用于制备药物组合物的方法容易可行并且不需要用于其实施的特定设备。用于制备所述化合物的方法的特征是高收率和纯度，在物质的制备和分离中使用环境清洁的溶剂‑乙醇和水，以及在终产物中没有残留有机溶剂。 | ||||||
| 9 | 包含3-甲酰基利福霉素SV和3-甲酰基利福霉素S的3-(4-肉桂基-1-哌嗪基)氨基衍生物的药物制剂以及它们的制备方法 | CN201380053241.6 | 2013-08-09 | CN104736152A | 2015-06-24 | R·G·康斯坦丁诺瓦; 基里尔·阿瑟诺夫·尼诺夫; 卫理士卡·里列瓦·阿波斯托洛娃-迪莫瓦; 伊夫提米亚·伊万诺瓦·斯戴凡诺瓦; 罗森·克鲁莫夫·科伊特切夫 |
| 本发明涉及制备包含作为活性物质的3-甲酰基利福霉素SV和3-甲酰基利福霉素S的3-(4-肉桂基-1-哌嗪基)-氨基衍生物的药学上可接受的制剂的方法，所述药学上可接受的制剂具有针对革兰氏阳性和革兰氏阴性微生物以及针对结核分枝杆菌(tuberculous micobacteria)(包括非典型的和利福霉素抗性的)的高活性，并且涉及用于制备3-甲酰基利福霉素SV和3-甲酰基利福霉素S的3-(4-肉桂基-1-哌嗪基)-氨基衍生物的方法。用于制备药物组合物的方法容易可行并且不需要用于其实施的特定设备。用于制备所述化合物的方法的特征是高收率和纯度，在物质的制备和分离中使用环境清洁的溶剂-乙醇和水，以及在终产物中没有残留有机溶剂。 | ||||||
| 10 | 利用選擇性細胞素(CYTOKINE)抑制藥物供治療及管控癌症及其它疾病之方法及組合物 METHODS AND COMPOSITIONS USING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES | TW092131072 | 2003-11-06 | TW200501945A | 2005-01-16 | 傑洛門B. 才迪斯 JEROME B. ZELDIS |
| 本發明係揭示治療、預防及／或管控癌症，以及有關於或其特徵在於不想要的血管生成作用之疾病和病症的方法。該特定方法包括單獨或與第二個活性成分併用，投予選擇性細胞素抑制藥物。本發明進一步更關於降低或避免與化學療法、輻射療法、荷爾蒙療法、生物學療法或免疫療法有關之有害副作用的方法，其包括投予選擇性細胞素抑制藥物。亦揭示適用於本發明之方法的醫藥組合物、單一單位劑量形式和套組。 | ||||||
| 11 | Organometallic complex and organic el element by utilizing the same | JP2007036903 | 2007-02-16 | JP2007224029A | 2007-09-06 | DAS RUPASREE RAGINI; KIM HEE-KYUNG; KWON O-HYUN; KIM MYEONG-SUK; TAMURA SHINICHIRO; PARK SHOSHIN; RYO GASHIN; RYU RIRETSU; BYUN YOUNG HUN |
| PROBLEM TO BE SOLVED: To provide an organometallic complex generating a high efficiency phosphorescence and an organic electric field light-emitting element by utilizing the same. SOLUTION: This organometallic complex is expressed by chemical formula: ML mL' n (chemical formula 1) [wherein, M is Ir, Os, Pt, Pb, Re, Ru or Pd; L and L' are different bidentate ligands; (m) is 1, 2 or 3; and (n) is (3-m)]. The organometallic complex is e.g. a compound having a structure of chemical formula 21, and used as a light-emitting layer-forming material of the organic electric field light-emitting element. COPYRIGHT: (C)2007,JPO&INPIT | ||||||
| 12 | Novel penicillin derivative and antibacterial comprising it | JP14609878 | 1978-11-28 | JPS5573690A | 1980-06-03 | MACHIDA YOSHIMASA; SAITOU ISAO; YAMANAKA MOTOSUKE; NOMOTO SEIICHIROU; NEGI SHIGETO; MINAMI NORIO; HAMAMURA KICHISABUROU; YAMAGISHI YOUJI; KITOU KIYOUSUKE; SATOU MASARU; KATSU KAMAMASA |
| NEW MATERIAL:A penicillin derivative of formula I: [R 1 is H, lower alkyl, or branched chain alkyl group; R 2, R 3, R 4, and R 5 are H, lower alkyl, or lower alkoxymethyl groups; A is H or hydroxyl group; B is direct bond, etc.; X is O, S, etc.; Y is O or methylene group; the dotted line in the ring is (un)saturated bond], and its non-toxic salt. EXAMPLE: D( - )α-[ 6-( 2,2,5,7,8-Pentamethylchromanyloxy )-actamido ]-benzylpenicillin. USE: Antibacterials, having a greater antibacterial activity and lower toxicity than ampicillin. PROCESS: A phenylglycylpenicillanic acid derivative is reacted with a compound of formula III or its reactive derivative in the presence of a basic reagent or silylating agent in an inert solvent, e.g. tetrahydrofuran, acetone, or furan, to give the compound of formula I. COPYRIGHT: (C)1980,JPO&Japio | ||||||
| 13 | EPOTHILON DERIVATIVES, THEIR PREPARATION PROCESS, INTERMEDIATE PRODUCTS AND THEIR PHARMACEUTICAL USE | PCT/EP1999/004915 | 1999-06-30 | WO00000485A1 | 2000-01-06 | |
| The invention relates to new epothilon derivatives of general formula (I) where the substituents Y, Z, R<1a>, R<1b>, R<2a>, R<2b>, R<3>, R<4a>, R<4b>, D-E, R<5>, R<6>, R<25>, R<7>, R<8> et X have the meaning given in the description. These new compounds co-operate with tubulin by stabilising formed microtubuli. They are able to affect cell splitting in a phase-specific way and are useful for the treatment of malignant tumours, such as ovarian, stomach, colon, lung, head or neck cancer, adenocarcinoma, malignant melanoma and acute lymphoid and myeloid leukaemia. They are also adapted to anti-angiogenesis therapy and to treatment of chronic inflammation diseases (psoriasis, arthritis). These new compounds can be applied on polymer materials or introduced therein to avoid uncontrolled proliferation on medical implants and to improve tolerance of these medical implants. The inventive compounds can be used alone or in combination with other ingredients or classes of substances which can be used in tumour therapy to obtain respectively additional actions or synergistic effects. | ||||||
| 14 | 유전공학 기법을 이용한 인체 인슈린의 새로운 유전자 설계 및 이를 이용한 인체 인슈린의 제조 | KR1019880001498 | 1988-02-15 | KR100035971B1 | 1990-09-13 | 이대실; 김명희; 남두현; 박병철; 임향숙 |
| 15 | USE OF BRAIN NATRIURETIC PEPTIDES (BNP), PHOSPHORYLATED URODILATINE, PHOSPHORYLATED CDD/ANP AND COMBINATIONS THEREOF | PCT/EP1994001237 | 1994-04-20 | WO1995028952A1 | 1995-11-02 | HAEMOPEP PHARMA GMBH |
| The invention concerns the use of a pharmaceutical composition, brain natriuretic peptides (BNP), phosphorylated urodilatine (P-uro), phosphorylated ANP (P-CDD/ANP) and combinations thereof and possibly pharmaceutically conventional thinners, carriers, fillers or auxiliary substances for treating lung and bronchial disorders. | ||||||
| 16 | 요소기함유 오르가노실리콘화합물, 그 제조방법 및 그 사용방법 | KR1019997005750 | 1997-12-18 | KR100323308B1 | 2002-02-06 | 오버네터스테판; 헥틀볼프강; 필스베거에리흐; 필루슈도리스; 스텝미켈 |
| 본발명은다음일반식(I)의단위의최소한 3개의실리콘원자를가진오르가노실리콘화합물에관한것이다. RSi(NRC=ONR)(NRC=ONR)YO[(CR)](Ⅰ) 위식에서, Y는다음일반식(Ⅱ)의단위를나타낸다. -SiR(NRC=ONR)(NRC=ONR)(Ⅱ) R, R,R,R,R,R및 R은각각의경우서로각각같거나다르며, 수소원자또는탄소원자 1-20개를가진선택치환시킨 1가의탄화수소래디컬이고, a,k,t,n,m,r,s,p 및 q은제 1 항에서설명한의미를가진다. 단, p+q의합은≤3이고, a+k+t+m+n+r의합은 4이며, m+r의합은 0 또는 1이고, 본발명에의한오르가노실리콘화합물은일반식(I)(여기서 t는 0을제외함)의최소한 1개의단위를포함함. | ||||||
| 17 | 요소기함유 오르가노실리콘화합물, 그 제조방법 및 그 사용방법 | KR1019997005750 | 1997-12-18 | KR1020000062316A | 2000-10-25 | 오버네터스테판; 헥틀볼프강; 필스베거에리흐; 필루슈도리스; 스텝미켈 |
| 본발명은일반식(I)의단위로된 적어도 3개의실리콘원자를가진오가노실리콘화합물에관한것이다. RaSi(NRC=ONR)(NRC=ONR)YmOn/2[(CR)](Ⅰ) 여기서, Y 는일반식(Ⅲ)의단위이다. -SiR(NRC=ONR)(NRC=ONR)(Ⅱ) 여기서, R,R,R,R,R,R는모든경우서로독립적이며동일또는상이하며, 또 1개의수소원자또는 1~20탄소원자를가진임의로치환된 1가탄화수소래디컬이다. a,k,t,n,m,r,s,p 및 q 는다음조건하에청구항 1 에서주어진의미를가진다. -합계 p+q 는≤3 이다. -합계 a+k+t+m+n+r 은 4 이다. -합계 m+r 은 0 또는 1 이다. 그리고 - 본발명에의한오가노실리콘화합물은일반식(I)의적어도 1개단위를함유한다. 이때 t 는 0 이아니다. | ||||||
| 18 | 칼시토닌살몬유사체와이들을이용한제제및이들의의약용과분석제로서의용도 | KR1019970705486 | 1996-02-02 | KR1019980702091A | 1998-07-15 | 파올로알베르토베로네시; 안나마리아베로네시; 엠마뉴엘라페스체체라 |
| 본 발명은 다음 서열로 나타낸 바와 같이 신규한 치환 살몬 칼시토닌(살카토닌) 유사체에 관한 것으로써, 여기서 R 1 은 -Cys-SH 또는 Cys-S-OH 또는 탄소원자수 2 ~ 5인 알킬기의 에테르 또는 이들의 에스터이거나 또는 약제학적으로 수용가능한 이들의 염 또는 이성질체이며; R 2 는 수소원자 또는 히드록시기 또는 탄소원자수 2 ~ 5인 알킬기의 에테르 또는 이들의 에스터 또는 약제학적으로 수용가능한 이들의 염 또는 이성질체이거나 또는 아세토아마이도메틸 또는 이들의 동등체이다. 이들 유사체는 골다공증, 고칼슘혈증, 파제트씨병과 같은 질환의 예방·치료에 의학적 특성을 갖고 있으며 또한 분석제로서 유용하다. | ||||||
| 19 | Antistatic composition and elements and processes utilizing same | US338401 | 1982-01-08 | US4415626A | 1983-11-15 | Charles R. Hasenauer; Donald N. Miller |
| An antistatic composition useful to reduce the propensity of multilayer elements to accumulate static electrical charge comprises an aqueous dispersion of (a) a film-forming binder; (b) a hardener for the binder; (c) a substantially transparent matting agent having particles with a diameter in the range of from about 1 to about 50 microns and a specific gravity substantially the same as that of water; (d) a highly electrically conductive, noncrystallizable conductivity agent; and (e) a charge control agent. This antistatic composition is especially useful as an image-receiving layer on substantially transparent image-receiving elements. Such image-receiving elements can be formed into projection-viewable transparencies by an electrographic copy process, which transparencies are considerably less likely to stick to one another or jam in electrographic copier/duplicator equipment than currently available transparencies. | ||||||
| 20 | Thermoelectric materials and elements utilizing them | US60925556 | 1956-09-11 | US2902529A | 1959-09-01 | BUSANOVICH CHARLES J |
QQ群二维码
意见反馈
意见反馈